How will CCR5 antagonists influence the recommendations for the antiretroviral treatment of HIV-1 infection

European Journal of Medical Research

Volumn 12, Issue 9, 2007, Pages 435-440

  van Lunzen, Jan ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; COTRIMOXAZOLE; CYTOCHROME P450 3A4 INHIBITOR; CYTOCHROME P450 INHIBITOR; DARUNAVIR; DELAVIRDINE; EFAVIRENZ; ENFUVIRTIDE; KETOCONAZOLE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR; TIPRANAVIR; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; VICRIVIROC; VIRUS RNA;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BRONCHITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED CANCER; DRUG INHIBITION; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HEPATITIS B; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION; LIPID METABOLISM; LIVER TOXICITY; MONOTHERAPY; PATIENT SELECTION; QT INTERVAL; RHINOPHARYNGITIS; SALVAGE THERAPY; SIDE EFFECT; SUPERINFECTION; TREATMENT PLANNING; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VIRUS INHIBITION; VIRUS LOAD; VIRUS RESISTANCE; VIRUS STRAIN;

ANTI-HIV AGENTS; CLINICAL TRIALS AS TOPIC; CYCLOHEXANES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RECEPTORS, CCR5; TRIAZOLES;

EID: 35548992732     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Brumme ZL, Goodrich J, Mayer HB et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005;192:466-74.
2. Cahn P, Villacian J, Lazzarin A et al. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. C]in Infect Dis 2006;43:1347-5.
3. Chan DC, Kim PS. HIV entry and its inhibition. Cell 1998;93:681-4.
4. Deng H, Liu R, Ellmeier W et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381:661-6.
5. Dragic T, Litwin V, Allaway GP et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381:667-73.
6. Faetkenheuer G, Pozniak A, Johnson MA et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005;11:1170-2.
7. Gathe J, Cooper DA, Farthing C et al. Efficacy of protease inhibitors tipranavir plus ritonavir in treatment experienced patients: 24-week analysis from the RESIST-1 trial. Clin Infect Dis 2006;43:1337-46.
8. Gulick R, Su Z, Flexner C. et al: ACTG 5211: phase II study of the safety and efficacy of vicriviroc (VCV) in HIV-infected treatment-experienced subjects: 48 week results. 4th IAS Conference 2007, Abstract no. TUAB102
9. Lalezari JP, Henry K, O'Hearn M et al. Enfuvirtide, and HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Eng J Med 2003;348: 2175-85.
10. Lazzarin A, Clotet B, Cooper D et al. Efficacy of enfuvirtide in patients infected with drug-reistant HIV-1 in Europe and Australia. N Eng J Med 2003;348:2186-95.
11. Limoli K, Whitcomb J, Kiss L et al. Techincal validation defines the performance of Monogram's HIV coreceptor tropism assay. AIDS 2006 - XVI International AIDS Conference. 2006;Abstract no. THPE0045.
12. Moore JP, Kitchen S, Pugach P et al. The CCR5 and CXCR4 coreceptors - central to understanding the transmission and pathogenesis of the human immunodeficiency virus type 1 infection. AIDS Res Human Retrovir 2004;20:111-26.
13. Moyle GJ, Wildfire A, Mandalia S et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005;191:866-72.
14. Petropoulos CJ, Parkin NT, Limoli KL et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000;44:920-8.
15. Saag M, Ive P, Heera J et al.: A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/ lamivudine [3TC]), for the treatment of antiretroviral naive subjects infected with R5 HIV-1: week 48 results of the MERIT study. 4th IAS Conference 2007, Abstract no. WESS104
16. Shankarappa R, Margolick JB, Gange SJ et al. Consistent viral evolutionary changes associated with the progression of human immunodefiency virus type 1 infection. J Virol 1999;73:10489-502.
17. Thio CL, Astemborski J, Bashirova A, Mosbruger T, Greet S, Witt MD, Goedert JL, Hilgartner M, Majeske A, O'Brien S, Thomas DL, Carrington M. Genetic protection against hepatitis B virus conferred by CCR5delta32: Evidence that CCR5 contributes to viral persistence. J Virol 2007; 81: 441-445.
18. Westby M, Lewis M, Whitcomb J et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006; 80: 4909-20.
19. Westby M, Smith-Burchnell C, Mori J et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007; 81: 2359-71.
20. Whitcomb JM, Huang W, Fransen S et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 co-receptor tropism. Antimicrob Agents Chemother 2007;51:566-75.
21. Wilkin TJ, Su Z, Kuritzkes DR et al. HIV type 1 chemokine receptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 2007; 44:591-5.
22. Wyatt R, Kwong PD, Desjardins E, Sweet RW et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998;393:705-11.
23. Zhu T, Mo H, Wang N et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993;261:1179-81.